ABSTRACT
Liberalization facilitated Indian firms to market generics drugs to the USA and other Western European countries. Indian firms are aiming to move up the value chain by developing capabilities to produce super generics and branded generics. Indian companies have realized that to compete with the global pharmaceutical companies, even in the domestic market, they need new strategies and greater innovation. Identifying the growth of domestic and foreign demand, most Indian pharmaceutical companies aimed at expanding their manufacturing capacities mostly by means of M&A. Drive to get market access, new technologies, enhances the size and thereby attaining higher economies of scale could be considered as key motivations for M&A in pharmaceutical sector (Vyas, Narayanan, and Ramanthan 2012).
